Literature DB >> 19269801

Comparative in vitro evaluation of four corticosteroid metered dose inhalers: Consistency of delivered dose and particle size distribution.

Tjalling W de Vries1, Bart L Rottier, Doetie Gjaltema, Paul Hagedoorn, Henderik W Frijlink, Anne H de Boer.   

Abstract

INTRODUCTION: Recent developments concerning pressurized metered dose inhalers (pMDIs) with inhaled corticosteroids (ICS) are the introduction of ciclesonide and the replacement of propellants. As the results of in vivo studies depend on pMDIperformance, it is necessary to evaluate pMDIs in vitro for delivered dose and particle size distributions under different conditions.
METHODS: Fluticasone 125microg, budesonide 200microg, beclomethasone HFA100microg, and ciclesonide 160microg were compared for delivered dose and particle size using laser diffraction analysis with inspiratory flow rates of 10, 20 and 30l/s.
RESULTS: The volume median diameter of budesonide was 3.5microm, fluticasone 2.8microm, beclomethasone and ciclesonide both 1.9microm. The mouthpiece retention was up to 30% of the nominal dose for beclomethasone and ciclesonide, 11-19% for the other pMDIs. Lifespan, flow rate, and air humidity had no significant influence on particle size distribution. The delivered dose of beclomethasone, budesonide, and ciclesonide remained constant over the lifespan. The delivered dose of fluticasone 125 decreased from 106% to 63%; fluticasone 250 also decreased whereas fluticasone 50 remained constant.
CONCLUSIONS: There is a significant difference in median particle size distribution between the different ICS pMDIs. Air humidity and inspiratory flow rate have no significant influence on particle size distribution. Ciclesonide 160 and beclomethasone 100 deliver the largest fine particle fractions of 1.1-3.1microm. The changes in delivered dose during the lifespan for the fluticasone 125 and 250 may have implications for patient care.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19269801     DOI: 10.1016/j.rmed.2009.02.010

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  2 in total

1.  Inhaled hydrofluoalkane-beclomethasone dipropionate in bronchopulmonary dysplasia. A double-blind, randomized, controlled pilot study.

Authors:  A Kugelman; M Peniakov; S Zangen; Y Shiff; A Riskin; A Iofe; I Shoris; D Bader; S Arnon
Journal:  J Perinatol       Date:  2016-10-13       Impact factor: 2.521

2.  From inhaler to lung: clinical implications of the formulations of ciclesonide and other inhaled corticosteroids.

Authors:  Ruediger Nave; Helgert Mueller
Journal:  Int J Gen Med       Date:  2013-03-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.